Under a new agreement, Coya Therapeutics’ amyotrophic lateral sclerosis (ALS) treatment candidate COYA 302 — which aims to suppress chronic and sustained inflammation — will now be exclusively marketed by Dr. Reddy’s Laboratories in the U.S., Canada, and the U.K., as well as in the European Union, should…
News
The ALS Association has given Oryzon Genomics nearly $500,000 to advance ORY-4001, a potential treatment of amyotrophic lateral sclerosis (ALS), into preclinical studies. The $498,690 grant was provided via the association’s Lawrence and Isabel Barnett Drug Development Program. Oryzon intends for laboratory studies in mouse disease models…
NeuroSense Therapeutics’ PrimeC was found to be safe and well tolerated in a Phase 2b trial, and use of the oral therapy for six months led to “meaningful slowing of disease progression” in people with amyotrophic lateral sclerosis (ALS), the company said in a press release announcing top-line…
Genetic and clinical factors that can influence how amyotrophic lateral sclerosis (ALS) progresses were identified in a recent analysis of data from PRECISION-ALS, a large European research project. Consistent with known risk factors for ALS progression, C9ORF72 genetic mutations, bulbar-onset disease, and faster functional declines were linked…
Colchicine, an anti-inflammatory medication used to treat gout, was safe, but did not significantly slow the progression of amyotrophic lateral sclerosis (ALS) in a small Phase 2 clinical trial. While some clinical measures suggested a possible benefit of a low dose of colchicine in slowing disease progression and extending…
Eating foods with a higher glycemic index — those more likely to quickly raise a person’s blood sugar — is associated with slower functional declines and prolonged survival among people with amyotrophic lateral sclerosis (ALS), according to a recent analysis. Foods with high amounts of sugar include white bread…
Amylyx Pharmaceuticals is developing AMX0114, a new experimental treatment for amyotrophic lateral sclerosis (ALS) that’s designed to promote the health of nerve fibers by lowering levels of calpain-2, a protein. AMX0114 is being tested in preclinical studies with the aim of supporting an investigational new drug application (IND),…
Anxiety is common among people newly diagnosed with amyotrophic lateral sclerosis (ALS) and their family members, a small study from Sweden reports. However, symptoms of anxiety tended to ease about six or so months later for patients, while they continued to affect relatives, many who are caregivers, two years…
A Phase 1b proof-of-concept clinical trial of the experimental oral therapy VRG50635 in people with amyotrophic lateral sclerosis (ALS) is expected to launch in the coming months, according to the therapy’s developer, Verge Genomics. Verge also announced that the upcoming trial will use Modality.AI, a…
Health Canada has cleared ProJenX to open the third part of its ongoing Phase 1 clinical trial and begin testing the experimental therapy prosetin in people with amyotrophic lateral sclerosis (ALS). The first two parts of the PRO-101 trial (NCT05279755) involved healthy participants and showed that the…
Recent Posts
- ‘Early birds’ have significantly lower ALS risk than ‘night owls’: Study
- As my late husband’s ALS progressed, we kept our bucket list simple
- Tossing and turning over fears this ALS journey has come to its end
- Experimental ALS therapy QRL-201 shows potential to slow disease decline
- Worried about an inability to multitask? Here’s what helped me.